Poliovirus vaccination during the endgame: insights from integrated modeling. (Q39258694)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28437234%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

title

Poliovirus vaccination during the endgame: insights from integrated modeling (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28437234%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28437234%20AND%20SRC:MED&resulttype=core&format=json

Radboud J Duintjer Tebbens

18 March 2020

series ordinal

1

object named as

Radboud J Duintjer Tebbens

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28437234%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

publication date

9 May 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28437234%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Vaccines

18 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28437234%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28437234%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28437234%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

page(s)

577-586

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28437234%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

18 March 2020

copyright license

start time

22 June 2021

1 reference

https://api.crossref.org/v1/works/10.1080/14760584.2017.1322514

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Modeling population immunity to support efforts to end the transmission of live polioviruses

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

Modeling the dynamics of oral poliovirus vaccine cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

Environmental Isolation of Circulating Vaccine-Derived Poliovirus After Interruption of Wild Poliovirus Transmission - Nigeria, 2016.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

Preeradication vaccine policy options for poliovirus infection and disease control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

Evaluation of response scenarios to potential polio outbreaks using mathematical models

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

Optimal vaccine stockpile design for an eradicated disease: application to polio.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

An economic analysis of poliovirus risk management policy options for 2013-2052

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

Framework for Optimal Global Vaccine Stockpile Design for Vaccine-Preventable Diseases: Application to Measles and Cholera Vaccines as Contrasting Examples

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

Modeling options to manage type 1 wild poliovirus imported into Israel in 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

Decay of Sabin inactivated poliovirus vaccine (IPV)-boosted poliovirus antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

Lessons From the Polio Endgame: Overcoming the Failure to Vaccinate and the Role of Subpopulations in Maintaining Transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

Increasing Type 1 Poliovirus Capsid Stability by Thermal Selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1322514

10.1080/14760584.2017.1322514

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28437234%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference